Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Vanguard Real Estate Index Fund ETF trades at $96.4. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VNQ | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | — |
52-Week High | $6.79 | $100.95 |
52-Week Low | $2.84 | $87.00 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
VNQ, the Vanguard Real Estate ETF, trades at $97.13, up 0.02% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. The ETF offers a dividend of $0.86 scheduled for June 2026, but key valuation ratios like P/E and P/B are unavailable. Recent news highlights institutional selling and comparisons with global real estate ETFs, emphasizing VNQ's U.S. REIT focus and low fees.
Outlook: VNQ faces headwinds from bearish technicals and institutional outflows, but its low expense ratio and U.S. real estate exposure provide stability. Risks include interest rate sensitivity and underperformance versus broader markets, as noted in long-term return comparisons. Investors should weigh dividend income against sector volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
